Molecular Pharmacology Program

The David Scheinberg Lab

Research

David Scheinberg
David A. Scheinberg, MD, PhD
Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science. 

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021)

Research Projects

The David Scheinberg Lab

Publications

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

View All Publications

People

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

  • Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
  • MD, PhD, Johns Hopkins University School of Medicine
[email protected]
Email Address
646-888-2190
Office Phone
View physician profile
Physician profile

Members

Michael Curcio

Research Assistant

Tao Dao

Senior Research Scientist

Tatyana Korontsvit

Research Assistant

Michael McDevitt
Michael R. McDevitt

Laboratory Member

Zita Aretz
Zita Aretz

Graduate Student

Winson Cai

Graduate Student

Annelisa Cornel

Research Fellow

Samarah Forbes

Senior Administrative Assistant

Keifer Kurtz
Keifer Kurtz

Graduate Student

Michael X. Lau
Michael X. Lau

Pediatric Hematology/Oncology Fellow

Josh Jaeyop Lee

Hematology/Oncology Fellow

Qianqian (Skylar) Lin

Graduate Student

Manish Malviya
Manish Malviya

Senior Research Scientist

Jeremy P. Meyerberg

Research Technician

Stephanie Pierre, BS
Stephanie Pierre

Graduate Student

Ekaterina Revskaya
Ekaterina Revskaya

Senior Research Scientist

Kristen Vogt
Kristen Vogt

Graduate Student

Patrick Wallisch, MSc
Patrick Wallisch

Graduate Student

Lab Alumni
Emily C. Casey, BS
Emily C. Casey

Principal Scientific Communication Lead at Genentech, San Francisco, CA

Aaron Chang

Graduate Student

Freddie Escorcia
Thomas J. Gardner, PhD
Thomas J. Gardner

Research Fellow

Ron Gejman
Ron Gejman

Graduate Student

William Maguire

Graduate Student

Prabodhika Mallikaratchy, PhD
Prabodhika Mallikaratchy

Visiting Scientist

Justin J. Mulvey

Graduate Student

Andrew Scott

Research Technician

Jonathan Seideman

Graduate Student

Nicholas Veomett

Graduate Student

Carlos Villa

Graduate Student

Sam Wong

Graduate Student

Victoriya Zakhaleva, Research Technician
Victoriya Zakhaleva

Research Technician

Bryan Aristega

Research Technician

Mamadou A. Bah

Lab Rotation SEP-DEC 2020

Christopher Bourne
Christopher Bourne

Graduate Student

Allison Clement

Research Technician

Megan Dacek
Megan Dacek

Graduate Student

Barbara de Mello
Barbara De Mello

Research Assistant

James Han

Research Associate

Casey Jarvis

Research Technician

Heather Jones

Graduate Student

Martin G. Klatt

Research Fellow

Melissa Mathias

Research Fellow

Sung Soo Mun

Research Assistant

Leila Peraro

Research Scholar

Lab Affiliations

Lab News & Events

Journal Club & Photo Album

Get in Touch

Lab Resources

To learn more about Postdoc compensation and benefits at MSK, please visit https://www.mskcc.org/education-training/postdoctoral/resources-postdocs/compensation-benefits-resources

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Equity; Intellectual Property Rights; Professional Services and Activities
  • Arvinas, Inc.
    Equity
  • Atengen, Inc.
    Equity; Professional Services and Activities (Uncompensated)
  • Bridge Medicines
    Professional Services and Activities (Uncompensated)
  • CoImmune, Inc.
    Equity; Intellectual Property Rights; Professional Services and Activities
  • Eureka Therapeutics Inc
    Equity; Professional Services and Activities
  • Great Point Partners
    Equity; Professional Services and Activities
  • Iovance Biotherapeutics, Inc.
    Equity
  • Lantheus Medical Imaging, Inc.
    Equity
  • OncoPep, Inc.
    Professional Services and Activities
  • Pfizer, Inc.
    Equity; Professional Services and Activities
  • Repertoire Immune Medicines, Inc.
    Professional Services and Activities
  • Sapience Therapeutics, Inc.
    Equity; Fiduciary Role / Position
  • Sellas Life Science Group
    Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures